source
- Pfizer and Amgen target GLP-1 weight-loss market to rival Novo Nordisk and Eli LillyThe STATus Report video hosted by Alex Hogan discusses the growing GLP-1 weight-loss drug market. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years and are pop…
- F2G and Shionogi report positive Phase 3 results for antifungal candidate olorofimF2G and Shionogi announced that their joint antifungal candidate, olorofim, met the primary endpoints in a Phase 3 trial. The data were released Thursday morning and showed the drug performed compa…